MD Anderson Cancer Center showed that first-line treatment with axicabtagene ciloleucel (axi-cel), an autologous anti-CD19 CAR T-cell therapy, achieved a high rate of complete response in patients with high-risk large B-cell lymphoma.
In a phase Ib/II clinical trial known as EPCORE NHL-2, a team of researchers—led by Joshua Brody, director of the Lymphoma Immunotherapy Program at the Tisch Cancer Institute at Mount Sinai—showed the benefit of combining chemotherapy with immunotherapy for diffuse large B-cell lymphoma. The results were published earlier this month in the journal Blood.
